S-1/A: Cardiff Lexington Corporation Responds to SEC Comments in Amended S-1 Filing

Cardiff Lexington Corporation files an amendment to its Form S-1 registration statement, addressing comments from the SEC and updating financial information.

Summary

• Cardiff Lexington Corporation filed Amendment No. 4 to its Form S-1/A registration statement with the SEC on May 31, 2024.
• The filing includes updated financial data for the three months ended March 31, 2024, and the years ended December 31, 2023, and 2022.
• The company is offering 1,600,000 shares of common stock, with an estimated public offering price between $4.00 and $6.00 per share.
• The closing of the offering is contingent upon the company's uplisting to The Nasdaq Capital Market under the symbol CDIX.
• The company intends to use the net proceeds from the offering for working capital and general corporate purposes.
• The company operates primarily in the healthcare industry through its subsidiary Nova Ortho and Spine, and also owns a real estate company, Edge View Properties.
• All revenue is generated by the healthcare business, which generated revenue of $11,853,266 and $10,693,196 for the years ended December 31, 2023 and 2022, respectively.
• For the year ended December 31, 2023, the company had a net income of $3,028,394, as compared to a net loss of $5,429,521 for the year ended December 31, 2022.
• For the three months ended March 31, 2024 and 2023, the company had a net loss of $283,104 and $15,991, respectively.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there's a positive shift from net loss to net income year-over-year, the recent quarterly results show a net loss, and there are going concern uncertainties. The potential uplisting to Nasdaq and the capital raise are positive developments, but the risks associated with the company's acquisition strategy and potential stock volatility temper the overall outlook.

Positives

• The company achieved net income of $3,028,394 in 2023, a significant improvement from the net loss of $5,429,521 in 2022.
• The company's healthcare revenue increased from $10,693,196 in 2022 to $11,853,266 in 2023.
• The company is pursuing an uplisting to The Nasdaq Capital Market, which could increase visibility and access to capital.

Negatives

• The company had a net loss of $283,104 for the three months ended March 31, 2024.
• The company's independent auditor has raised substantial doubt about its ability to continue as a going concern.
• The company has a significant accumulated deficit of $68,684,115 as of December 31, 2023.

Risks

• The company's ability to continue as a going concern is dependent on obtaining additional financing.
• The company's acquisition strategy exposes it to substantial risk, including the failure to identify material problems during due diligence.
• The market price of the company's common stock may be highly volatile, and investors could lose all or part of their investment.
• The company's officers and directors own a significant percentage of the company's outstanding voting securities, which could reduce the ability of minority stockholders to effect certain corporate actions.
• The company may not be able to satisfy Nasdaqs listing requirements or maintain a listing of its common stock on Nasdaq.

Future Outlook

The company expects to maximize organic growth by deploying increased working capital to expand utilization at its current healthcare facilities, open additional locations, and consider select synergistic acquisitions in the healthcare sector.

Industry Context

The healthcare industry is highly competitive, with increasing competition among providers for patients and a trend toward cost containment by both government and private payers.

Related Party Transactions

• The company obtained short-term advances from Daniel Thompson, the Chairman of the Board, that are non-interest bearing and due on demand.
• On August 25, 2023, the company issued a convertible promissory note in the principal amount of $5,000 to Alex Cunningham, our Chief Executive Officer.

Stakeholder Impact

• Shareholders may experience dilution from the offering of new shares.
• Employees may benefit from increased working capital and potential acquisitions.
• Customers may benefit from improved services and expanded locations.
• Suppliers may benefit from increased business activity.

Next Steps

• The company aims to complete its uplisting to The Nasdaq Capital Market.
• The company intends to close the offering of 1,600,000 shares of common stock.
• The company plans to deploy the net proceeds from the offering for working capital and general corporate purposes, including potential acquisitions.

Key Dates

Keywords

S-1/A, registration statement, common stock, healthcare, acquisition, Nasdaq, financial results, Cardiff Lexington Corporation